| 1  | Reverse mutational scanning of spike BA.2.86 identifies epitopes  |
|----|---|
| 2  | contributing to immune escape from polyclonal sera  |
| 3  | Najat Bdeir <sup>1</sup> , Tatjana Lüddecke <sup>1</sup> , Henrike Maaß <sup>1</sup> , Stefan Schmelz <sup>2</sup> , Ulfert Rand <sup>3</sup> , Henning |
| 4  | Jacobsen <sup>1</sup> , Kristin Metzdorf <sup>1</sup> , Upasana Kulkarni <sup>1</sup> , Anne Cossmann <sup>4</sup> , Metodi V. Stankov <sup>4</sup> ,   |
| 5  | Markus Hoffmann <sup>5,6</sup> , Stefan Pöhlmann <sup>5,6</sup> , Wulf Blankenfeldt <sup>2,7</sup> , Alexandra Dopfer-Jablonka <sup>4,8</sup> ,         |
| 6  | Georg M.N. Behrens <sup>4,8,9#</sup> , Luka Čičin-Šain <sup>*1,8,9#</sup>   |
| 7  | <sup>1</sup> Department of Viral Immunology, Helmholtz Centre for Infection Research, Braunschweig,   |
| 8  | Germany   |
| 9  | <sup>2</sup> Department Structure and Function of Proteins, Helmholtz Centre for Infection Research   |
| 10 | Braunschweig, Germany   |
| 11 | <sup>3</sup> DSMZ- German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany   |
| 12 | <sup>4</sup> Department of Rheumatology and Immunology, Hannover Medical School, Hannover,  |
| 13 | Germany   |
| 14 | <sup>5</sup> Infection Biology Unit, German Primate Center – Leibniz Institute for Primate Research,  |
| 15 | Göttingen, Germany  |
| 16 | <sup>6</sup> Faculty of Biology and Psychology, University Göttingen, Göttingen, Germany  |
| 17 | <sup>7</sup> Institute for Biochemistry, Biotechnology and Bioinformatics, Technische Universität   |
| 18 | Braunschweig, Braunschweig, Germany   |
| 19 | <sup>8</sup> German Center for Infection Research, partner site Hannover-Braunschweig, Hannover,  |
| 20 | Germany   |
| 21 | <sup>9</sup> Centre for Individualized Infection Medicine, a joint venture of HZI and Hannover Medical  |
| 22 | School, Hannover, Germany   |
| 23 | # These authors contributed equally *For correspondence: Luka Čičin-Šain: Luka.Cicin-   |
|    |   |

- Sain@helmholtz-hzi.de 24
- 25 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 26 ABSTRACT

27 The recently detected Omicron BA.2.86 lineage contains more than 30 amino acid 28 mutations relative to BA.2. BA.2.86 and its JN.1 derivative evade neutralization by serum 29 antibodies of fully vaccinated individuals. In this study, we elucidate epitopes driving the 30 immune escape of BA.2.86 and JN.1 via pseudovirus neutralization. Thus, we have 31 generated 33 BA.2.86 mutants, each reverting a single mutation back to BA.2. We use 32 this library in an approach that we call reverse mutational scanning to define distinct 33 neutralization titers against each epitope. Mutations within the receptor binding domain 34 at K356T, V483A, and to a lesser extent N460K, A484K, and F486P enhance immune escape. Interestingly, 16insMPLF within the spike N-terminal domain and P621S within 35 36 S1/S2 also significantly contribute to antibody escape of BA.2.86. Upon XBB.1.5 booster 37 vaccination, neutralization titers against JN.1 and BA.2.86 improve considerably, and a 38 residual immune escape is driven by 16insMPLF, N460K, E554K, and to a lesser extent 39 P621S, and A484K.

40

#### 41 EDITOR'S SUMMARY

42

43 SARS COV2 Omicron lineage BA.2.86 has over 30 mutations compared to the parental
44 BA.2 lineage. Here Bdeir and colleagues apply reverse mutational scanning to
45 determine which among these mutations present in Omicron BA.2.86 are epitopes
46 linked to immune escape from antibody recognition.

- 47
- 48

49

50

### 51 INTRODUCTION

The emergence of new SARS-CoV-2 virus lineages continues to be a critical aspect of the 52 ongoing epidemic viral spread. Among these lineages, BA.2.86, also known as Pirola, has 53 54 garnered recent attention owing to its significant antigenic shift away from the prevailing XBB sub-lineage <sup>2,3</sup>. The earliest detection of BA.2.86 was in late July 2023 in Denmark <sup>4-6</sup>. By mid-55 56 august, it had been detected within several countries and WHO had classified it as a variant of interest <sup>5-7</sup>. An outbreak of BA.2.86 recorded in the United Kingdom with a high attack rate 57 (86.6%) within an elderly care home demonstrated the transmissibility of this lineage <sup>8</sup>. At 58 59 present, the extent of disease severity exerted by BA.2.86 is unclear, but its derivative sub-60 variant JN.1 is on track to become the globally dominant SARS-CoV-2 lineage.

61 The viral spike (S) protein mediates SARS-CoV-2 host cell entry through a multistep process. 62 The initial step involves binding of the S protein to angiotensin converting enzyme-2 receptors (ACE2). This engagement is followed by S protein cleavage by host cell proteases, enabling 63 the S protein to drive fusion of the viral envelope with cellular membranes <sup>9</sup>. The S1 domain 64 65 of the S protein entails an N-terminal domain (NTD) with somewhat unclear functions, and the receptor-binding domain (RBD), which directly binds to ACE2 and is the major target for 66 neutralizing antibodies <sup>9-11</sup>. The transmembrane S2 domain drives viral fusion with the host 67 68 cell membrane, which facilitates the release of viral genetic material into the cytoplasm, and therefore plays an important role in infection. BA.2.86 harbors more than 30 mutations relative 69 to BA.2, encompassing 13 mutations in NTD, 14 in the RBD, and 7 within the pre S1/S2 and 70 S2 domain <sup>12</sup>. Furthermore, several BA.2.86 descendants have been identified, including 71 BA.2.86.1 (defining mutation ORF1a:K1973R), JN.1 (L455S), JN.2 (ORF1a:Y621C), JN.3 72 73 (ORF1a:T2087I), and BA.2.86.2 (ORF7a:E22D)<sup>3</sup>.

The alarming number of BA.2.86 spike mutations has prompted several efforts to characterize the antibody immune escape potential of this lineage. Recent studies demonstrate

76 reduced pseudo-virus neutralization of BA.2.86 and JN.1 in comparison to BA.2 and B.1 77 strains and that vaccination with the monovalent BNT162b2 XBB.1.5 adapted vaccine significantly enhances neutralization of BA.2.86 pseudo virus by serum antibodies <sup>13-15</sup>. 78 79 However, the contribution of single mutations to the immune escape of BA.2.86 remains unclear. Mutational scanning approaches, where libraries of viruses with single amino acid 80 81 mutations in the spike protein are compared to the wild-type virus are powerful tools for the identification of epitopes recognized by monoclonal antibodies <sup>16-18</sup>, but polyclonal serum 82 antibodies recognize numerous epitopes simultaneously and redundantly. Therefore, mutating 83 84 one out of 33 epitopes on an ancestral background may only marginally decrease the serum 85 neutralizing activity if some among the remaining 32 epitopes are recognized by independent 86 antibody clones. To overcome this limitation, we cloned a library of 33 reversion mutants on 87 the BA.2.86 background, each harboring a single mutation reverting the position back to the 88 amino acid in BA.2. This approach allowed us to observe a robust increase in neutralizing 89 activity whenever an immunologically relevant epitope was reintroduced in the spike. We 90 tested this library of BA.2.86 mutants against serum samples collected from a cohort of 30 91 healthcare workers, before and after vaccination with the BNT162b2 XBB.1.5 adapted vaccine. Our data showed that mutations ins16MPLF, K356T, N460K, V483A, A484K, F486P and 92 93 S621P distributed across NTD, RBD, and S1/S2 domains, contribute to the immune escape of 94 BA.2.86. Additionally, we show that vaccination with the BNT162b2 XBB.1.5 adapted 95 vaccine increases substantially the neutralization titers against both BA.2.86 and the more recent BA.2.86.1.1 (JN.1) descendant, and that the immune escape of JN.1 is more pronounced 96 97 than that of BA.2.86 before and after XBB.1.5 booster vaccination. Moreover, we demonstrate that the deletion of the MPLF insertion at position 16, reversions of N460K and K554E, and to 98 99 lesser extent the reinsertion of the tyrosine residue at position 144, as well as S621P and K484A 100 improve neutralization of BA.2.86 upon the XBB.1.5 booster shot.

#### 101 **RESULTS**

#### 102 **BA.2.86** spike protein harbors a substantial amount of mutations within all domains

The analysis of the BA.2.86 spike sequence (specifically: hCoV-19/Denmark/DCGC-103 104 647694/2023, EPI ISL 18114953) revealed 33 mutations relative to BA.2 spike (Figure 1). 105 These include 13 mutations within the NTD, 14 mutations in the RBD, and 6 mutations within 106 the S2 and pre S1/S2 domain. Of these mutations, there are five deletions (H69 $\Delta$ , V70 $\Delta$ ,  $Y144\Delta$ ,  $N211\Delta$ , and  $V483\Delta$ ) and one insertion after V16 (V16insMPLF). Among mutations 107 that have been previously identified in other variants of interest are R21T (B.1.617), 108 109 H69Δ/V70Δ (B.1.1.7/Alpha), Y144Δ (XBB.1.5; EG.5.1; BA.1), R158G (B.1.617.2/Delta), 110 E484K (B.1.351/Beta; P.1/Gamma) and P681R (B.1.617.2/Delta). Additionally, BA.2.86 111 harbors several mutations, which were rarely reported (V445H, N450D, N481K, V483A; and E554K) <sup>19-21</sup>. Among these mutations ins16MPLF, ΔY144, F157S, R158G, H245N, A264D 112 are located within the NTD antigenic supersite and may contribute to immune escape <sup>22</sup>. 113 114 Additionally, several mutations within the RBD of BA.2.86 have been associated with antibody resistance including K356T, A484K, and N450D<sup>10,23,24</sup>, while several other mutations R493Q, 115 F486P, N460K, and V483A may alter ACE2 interactions <sup>25,26</sup>. Hence, BA.2.86 contains a 116 plethora of mutations within the spike protein, which may alter key properties of this virus in 117 118 receptor binding and neutralizing antibody escape. To visualize the position of mutations in the spike protein of BA.2.86 with respect to BA.2, we used AlphaFold2/AlphaFold-Multimer<sup>27,28</sup> 119 120 to construct a structural model of the spike trimer of BA.2.86. The model, which was obtained 121 in a closed state with respect to the conformation of the RBD, shows that mutations with respect to BA.2 are spread over the distal part of the protein but otherwise do not cluster at specific 122 123 positions (Fig. 1B-C).

124

125

126

#### 127 BA.2.86 and JN.1 efficiently escape antibody neutralization

128 To assess the immune escape of the BA.2.86 and BA.2.86.1.1 (JN.1) lineages, we employed pseudo-virus particles (pp) in neutralization assays. For comparison, we also included particles 129 130 harboring the spike protein of XBB.1.5 (XBB.1.5<sub>pp</sub>), Wuhan-Hu-01 (WT<sub>pp</sub>), BA.1 (BA.1<sub>pp</sub>), and BA.2 (BA.2<sub>pp</sub>) (Figure 2A-B). We found that plasma obtained from a cohort of at least 131 132 double boostered individuals neutralized BA.1pp and BA.2pp 3-fold reduced efficiency as 133 compared to the index WT<sub>pp</sub>. However, the inhibition of BA.2.86<sub>pp</sub> and XBB.1.5<sub>pp</sub> was 57-134 and 48-fold reduced, respectively (Figure 2A). Antibody escape of JN.1<sub>pp</sub> was even more 135 pronounced, with a ~141-fold reduction relative to  $WT_{pp}$  (Figure 2A). Plasma acquired post 136 vaccination with the XBB.1.5-adapted mRNA vaccine neutralized XBB.1.5<sub>pp</sub> and BA.2.86<sub>pp</sub>, 137 with almost comparable efficiency, whereby the mean neutralization titer was 9-fold and 11fold lower than WT<sub>pp</sub>, respectively, while JN.1<sub>pp</sub> was 27 fold lower (Figure 2B). Collectively, 138 139 BA.2.86<sub>pp</sub> and JN.1<sub>pp</sub> escaped neutralization by antibodies induced upon primary vaccination 140 series and boosters with immunogens predating XBB lineages, whereby this escape was more 141 pronounced in JN.1. However, a vaccination with the XBB.1.5 adapted vaccine boosted the 142 neutralizing titers against both variants and reduced the gap in neutralization efficiency between them and Omicron BA.2. The neutralization efficiency of JN.1<sub>pp</sub> was ~2.4 fold 143 144 reduced relative to BA.2.86<sub>pp</sub>, before and after XBB.1.5 booster vaccination.

#### Mutations ins16MPLF, K356T, N460K, V483A, A484K, F486P, and P621S contribute to 145 146 BA.2.86 neutralizing antibody escape.

147 To investigate the effect of individual mutations within BA.2.86 on post-vaccination 148 neutralizing antibody escape, we cloned a comprehensive library of 33 individual BA.2.86 149 mutants. Each of them contains a single reversion relative to the amino acid sequence of BA.2,

150 while retaining the rest of the sequence as in BA.2.86. Geometric means of pseudo-virus 151 neutralization titers (PVNT50) against BA.2.86pp were ~18-fold lower than against BA.2pp prior 152 to vaccination with the XBB.1.5 vaccine (Figure 3A). Hence, we tested which mutations 153 decreased the gap between neutralization of BA.2<sub>pp</sub> and BA.2.86<sub>pp</sub>. Our data showed that among the BA.2.86<sub>pp</sub> mutants with single mutations within the NTD, only the insMPLF16 $\Delta_{pp}$ 154 155 reduced the gap to BA.2<sub>pp</sub> to a mere 4-fold reduction (Figure 3A). The remaining NTD<sub>pp</sub> single 156 mutants did not significantly contribute to neutralizing antibody escape, because their 157 neutralization titers were comparable to that of BA.2.86<sub>pp</sub> (Figure 3B). Moreover, we have shown in Zhang et al, that insMPLF16 $\Delta$  leads to a reduction of infectivity in VeroE6 cells<sup>29</sup>. 158 159 Hence, this unique NTD mutation is involved in both immune evasion from sera antibodies 160 and infectivity. While the N-terminus of BA.2.86 spike protein is modelled with lesser 161 confidence than the core of the structure (Figure S1A-C), it is interesting that the N-terminal 162 16MPLF insertion is predicted to interact with a crevice in the N-terminal domain (NTD; Figure S1B-C). This is reminiscent of SARS-CoV spike protein <sup>30</sup>, albeit here, the N-terminus 163 164 is yet more extended and anchored via a disulfide bridge to the core of the NTD (Figure S1D). Structural modelling from Colson et. al.<sup>31</sup> also suggest that insMPLF16 masks a V-shaped 165 166 electronegative zone within the NTD which might allow an advantage to stabilize the virus on target cells. It may also induce long range conformational rearrangements affecting the RBD 167 168 and potentially RBD-ACE2 interactions.

The neutralization capacity of serum samples against epitopes in the RBD of BA.2.86<sub>pp</sub> was significantly affected prior to the XBB.1.5 booster by the mutation K356T and  $\Delta$ V483, which had a 6 or 7 fold reduction in neutralization titer relative to BA.2, respectively (Figure 4A and 4B). Additionally, our results showed that K460N<sub>pp</sub>, , K484A<sub>pp</sub>, and P486F<sub>pp</sub> had a 6-, 7-, and 8-fold reduced neutralization efficiency, respectively, relative to BA.2<sub>pp</sub>, and thus much less than the 18-fold reduction observed in BA.2.86<sub>pp</sub>. While the latter results did not raise to

statistical significance over BA.2.86<sub>pp</sub> (Fig. 4B), they indicated an improved neutralization in
the presence of these parental epitopes. In contrast, the remaining mutations within the RBD
of BA.2.86 did not enhance serum neutralization capacity.

In addition to the aforementioned RBD and NTD BA.2.86 mutants, we explored the contribution of mutations within the S1/S2 and S2 regions to antibody evasion. We report a significant increase in neutralization efficiency for BA.2.86 S621P<sub>pp</sub>, whereby neutralization efficiency of BA.2.86 S621P<sub>pp</sub>. was 4-fold lower than that of BA.2<sub>pp</sub> and hence, significantly higher than for BA.2.86<sub>pp</sub> (Figure 5A and 5B) In contrast, BA.2.86 K554E<sub>pp</sub>, V570A<sub>pp</sub>, R681H<sub>pp</sub>, F939S<sub>pp</sub>, L1143P<sub>pp</sub> all showed comparable neutralization sensitivity as compared to BA.2.86<sub>pp</sub> (Figure 5A, and 5B).

185 Interestingly, the impact of BA.2.86 mutations on neutralization escape following vaccination 186 with the adapted XBB.1.5 immunogen revealed that the mutants insMPLF16 $\Delta_{pp}$ , K554E<sub>pp</sub>, and K460N<sub>pp</sub> significantly recovered the neutralization efficiency of plasma samples above 187 188 BA.2.86<sub>pp</sub> and to levels comparable to that of BA.2 neutralization (Figure 6). An increase in 189 neutralization efficiency after XBB.1.5 booster vaccination was observed for BA.2.86 mutants 190 S621P<sub>pp</sub>, ins144Y<sub>pp</sub> and K484A<sub>pp</sub>, but it did not raise to statistical significance, (Figure 6). 191 Further information on the post vaccination neutralization titers for each mutant pseudovirus 192 is provided in supplementary data (Figure S2 and Supplementary data 2). Since neutralization efficiency of JN.1<sub>pp</sub> was merely 2.4 fold reduced relative to BA.2.86<sub>pp</sub> after the XBB.1.5 193 194 booster vaccination, our data may argue that these positions may be relevant for the residual 195 immune escape of JN.1 upon the XBB.1.5 booster as well.

We previously reported that pseudovirus infectivity of Vero cells was significantly perturbed in  $\Delta$ ins16MPLF, K403R, D450N, Q493R, and S621P<sup>29</sup>. Since a reduction in infectivity may reflect an increase of dysfunctional virions in a stock, which would act as sponges for

neutralizing antibodies and compete with infectious particles <sup>1</sup>, we performed a digital droplet
PCR (ddPCR) of VSV-N stocks, thus defining the genome copy number relative to infectious
virus titers. For all tested mutants, these numbers were clustering between those of BA.2 and
BA2.86 (Supplementary information, Fig. S3). Therefore, our results all but exclude the
possibility that the neutralization titers were affected by the infectivity of the individual epitope
mutants.

205

207

206 **Discussion** 

208 This work provides to our knowledge the first example of a reverse mutational scanning 209 strategy for the identification of epitopes that contribute to immune escape from vaccine-210 induced immunity. Strategies based on mutational scanning of the SARS-CoV-2 spike are not 211 new. Others and we have shown that such approaches can be used to generate libraries 212 containing individual mutations present in the Omicron, but not in the ancestral variants, and thus identify epitopes that escape recognition by monoclonal antibodies <sup>17,18</sup> and polyclonal 213 sera <sup>1,16,17</sup>. A very comprehensive mutational scanning based on the XBB.1.5 spike has been 214 215 recently performed by the Bloom lab to introduce 9000 theoretical mutations on the XBB.1.5 background and thus predict future potential escape mutations <sup>16</sup>. However, forward mutational 216 217 scanning cannot predict the emergence of lineages with big evolutionary jumps, such as the 218 Omicron BA.1 and BA.2.86 variants, where more than 30 mutations were observed 219 simultaneously, with no intermittent stages that are known. Moreover, such approaches are not 220 ideal for the analysis of neutralizing potential of polyclonal sera, where redundant epitope 221 recognition may result in virus neutralization even if immunologically relevant epitopes are 222 mutated. Indeed, a forward mutational scanning approach that we have employed in a previous 223 study to assess Omicron epitope mutations on a Wuhan background showed only modest (<twofold) reductions in neutralization titers <sup>1</sup>. By reverse mutational scanning, we provide 224 225 here a loss-of-function genetic approach, allowing the identification of up to fourfold

differences in titers. Thus, we were able to identify escape epitopes in polyclonal responses to
antigens with many simultaneous mutations, defining the collection of epitopes that contribute
to immune escape from vaccine-induced immunity by BA.2.86 and its derivative JN.1 lineage.
This approach may also be rapidly deployed for subsequent lineages with big evolutionary
jumps that may emerge in the future.

231 The emergence of BA.2.86 harboring more than 30 mutations relative to BA.2 was reminiscent 232 of the Omicron appearance in 2021 and raised concerns regarding its antibody escape potential <sup>13,14,32</sup>. A number of these mutations (K356, V445, G446, N450, L452, and P621) were also 233 234 observed in omicron sub-lineages within immunocompromised patients. This may indicate that 235 reduced immune functions within some individuals may be a source of highly mutated SARS-236 CoV2 lineages <sup>33,34</sup>. BA.2.86 has also evolved several descendants including JN.1 which harbors three mutations in non S-proteins and a hallmark S455L mutation in the spike protein 237 238 <sup>3</sup>. In plasma from a cohort that was at least double boostered, we observed that the S455L 239 mutation reduces the neutralization efficiency relative to BA.2.86 by a factor of ~2.5, but that 240 the XBB.1.5 adapted vaccine booster increases neutralization efficiency against both lineages roughly ~12 to 13 fold, in line with data reported in Stankov et al. <sup>35</sup> and Wang et al. <sup>14</sup>. 241 Moreover, neutralization of BA.2.86<sub>pp</sub> and JN.1<sub>pp</sub> were merely 1.2-fold and 3 fold lower than 242 243 the neutralization of Omicron XBB.1.5 respectively. Nevertheless, their neutralization titers remain 6- and 16 fold lower than that of BA.2 following vaccination respectively. 244

Several mutations within BA.2.86 significantly increased the neutralizing antibody escape prior to vaccination with the adapted XBB.1.5 vaccine. We found that the NTD mutation ins16MPLF significantly affected neutralization sensitivity, and its reversion resulted in a 4fold increase in neutralization titers relative to BA.2.86. While this region of the NTD is disordered in published structures of the SARS-CoV-2 spike protein, indicating high intrinsic flexibility, the MPLF insertion is somewhat reminiscent of the SARS-CoV spike protein, where

251 the N-terminus is yet more extended and anchored via a disulfide bridge to the core of the NTD 252 (Fig. S1D). It should be noted that several NTD-binding neutralizing antibodies have been identified in the past <sup>36,37</sup>, indicating that mutations in this domain may indeed interfere with 253 254 the immune system's capacity to recognize the virus. Even more interestingly, we show that the deletion of the MPLF insertion at position 16 significantly increases neutralization 255 256 efficiency after the adapted XBB.1.5 vaccination to BA.2 comparable levels. This mutation is located within the NTD antigenic supersite, which is a key target for NTD specific neutralizing 257 antibodies <sup>22</sup>. Moreover, in silico structural modeling of BA.2.86 performed by Colson et al. 258 259 indicates that the MPLF insertion may mask a V-shaped electronegative zone within the NTD, 260 which is an unprecedented phenotype in SARS-CoV-2. This zone may stabilize the virus onto target cells and may induce some long-range conformational changes which affect the RBD 261 with potential consequences on RBD-ACE2 interactions <sup>31</sup>. However, our independent in silico 262 263 analysis of this region of the NTD structure argues that the changes at the N-terminal tip cannot be predicted with a high degree of confidence. Therefore, the actual effects of this mutation on 264 265 the NTD structure may only be confirmed by empirical analysis in cryoelectron microscopy or 266 similar approaches.

267 We also found that the mutation K356T within the RBD plays a contributing role to BA.2.86 escape of neutralization by polyclonal sera, whereby it lead to a six-fold reduction in 268 269 neutralization efficiency relative to BA.2<sub>pp</sub>, in comparison the 18 fold reduction in the case of 270 BA.2.86<sub>pp</sub>. This reduction in neutralization efficiency might be attributed to the steric hindrance caused by the introduction of an additional glycosylation site <sup>38</sup>. Similarly, we show that 271 272 mutations N460K, V483A, A484K, and F486P within the RBD may enhance neutralizing 273 antibody escape. This is in line with reports from Wang et al, which show that mutation N460K 274 and F486P shared in XBB.1.5 and EG.5.1 cause resistance to class 1 and 2 monoclonal antibodies (mAb)<sup>39</sup>. Structural modelling has shown that the mutation N460K, which was first 275

276 identified in BA.2.75, disrupts a hydrogen bond formed between the RBD and a class 1 mAb 277 (VH3-53)<sup>40</sup> and a study by Wang et al. demonstrated that the mutation A484K within BA.2.86 reduced the neutralizing activity of a subset of class 3 mAbs <sup>14</sup>. The mutation V483 $\Delta$  has 278 279 seldom been reported in circulating strains. Full spike mutational scanning of BA.2.86 280 postulated that V483 $\Delta$  may contribute to antibody escape but experimental evidence for this has been lacking <sup>16</sup>. We also show that the mutation P621S in the S1/S2 domain of BA.2.86 281 282 contributed to significant neutralization escape and this phenotype, to our knowledge has not 283 been demonstrated previously. In sum, we have identified several mutations that have 284 significantly contributed to immune escape in our cohort. However, we cannot exclude that 285 additional mutations may result in immune escape in individuals whose repertoire differs from 286 our cohort of double boostered individuals. This requires additional studies in cohorts of elderly 287 people or those with immune deficiencies. In parallel to our present study, we have conducted 288 a more thorough investigation to explore the effects of BA.2.86 specific mutations on infectivity and cell entry, including ACE-2 binding and protease usage <sup>29</sup>. We observed that 289 290 lung cell entry of BA.2.86 is ACE2 dependent and is markedly more efficient than that driven 291 by the S proteins of other omicron sublineages. To obtain insights into which amino acids are critical to this phenotype, we explored the infectivity of every pseudoviral mutant on Vero and 292 293 Calu-3 lung cells. This revealed that BA.2.86 specific mutations at NTD residue L50 and RBD 294 residue T356 specifically promote lung cell entry and bear no relevance for Vero cells' entry. 295 Several mutations affected cell entry into Vero cells, up to a sevenfold reduction in infectivity. 296 We have shown previously that mutant viruses with a hundred fold impaired infectiveness display a quantifiable reduction in neutralization serum titers due to the 297 298 preponderance of non-infectious virus particles in the virus stock that act as antibody sponges 299 in the neutralization assay <sup>1</sup>. Thus, we checked if the pseudovirus stocks showing significant differences in the cell entry assay into Vero cells <sup>29</sup> or in the neutralization assay had more non-300

301 infectious particles (Supplementary information, Fig. S3), but we observed no substantial 302 differences relative to the parental BA.2 or the index BA.2.86 strain. Hence, effects of 303 individual mutations on Vero cell infectivity was unlikely to have affected our neutralization 304 results.

305 It is also important to acknowledge some pertinent limitations relating to our study. We 306 have utilized the well-established pseudo-virus system to assess the contribution of single mutations to the antibody escape potential of BA.2.86. While formal verification would require 307 308 the use of authentic SARS-CoV-2 with spike mutations introduced by reverse genetics, 309 neutralization titers in pseudo-viral and authentic virus setups have been shown to be comparable due to the immunodominance of spike over other structural elements <sup>41-43</sup>. An 310 311 additional limitation in our study is the lack of information regarding hybrid immunity within 312 our cohort, whereby some participants may have experienced a prior unrecorded infection with 313 XBB sublineages, which may have elicited a humoral immune response similar to vaccination. 314 However, only 4 individuals have a recorded infection in 2023, when the XBB.1.5 lineage was 315 present at high levels.

316 In sum, BA.2.86 and its JN.1 descendent efficiently escape neutralization by polyclonal 317 serum antibodies of at least double boostered individuals, and our data argue that this is due to 318 mutations at positions N460K, V483A, A484K, F486P, K356T, P621S, and ins16MPLF. We 319 also observed that the S455L mutation provides a 2-fold decrease in neutralization titers over 320 BA.2.86. However, neutralization titers of JN.1 and BA.2.86 were appreciably improved by 321 the XBB.1.5 vaccine booster, whereby JN.1 has a mere 2.5 reduction relative to BA.2.86. This 322 may argue that residual immune escape of both lineages may rely on the shared epitopes at 323 positions ins16MPLF, E554K, N460K, and to lesser extent A484K and Y144A.

324

325

#### 326 Methods

#### 327 Cell lines

All cell lines were maintained at 37 °C and 5% CO2 in a humified environment. 293T (Human, 328 329 kidney) and VeroE6 (African green monkey, kidney) cells were cultured in Dulbecco's Modified Eagle Medium (DMEM, ThermoFisher Scientific) supplemented with 5% fetal 330 331 bovine serum (FBS, ThermoFisher Scientific) and 100 U/ml penicillin and 0.1 mg/ml Streptomycin (PAN-Biotec). Both cell lines were used to a maximum passage of 30. For 332 333 seeding and sub-cultivation, cells were washed with phosphate buffered saline (PBS, PAN-334 Biotec) and then incubated with trypsin/EDTA (PAN-Biotec) until cell detachment. Cell lines 335 were routinely tested for mycoplasma. The origin and catalogue numbers of cells are shown in 336 table 1, Supplementary data 3. Transfection of 293T cells for the production of pseudoviruses 337 was carried out by calcium phosphate transfection.

#### 338 Plasmids

339 The plasmid pCG1 SARS-2-Sdel18 (Codon-optimized) encoding the spike protein of the Wuhan-Hu-1 SARS-CoV-2 has been previously reported <sup>9</sup>. The pCG1 SARS-2-Sdel18 BA.1 340 and BA.2 expression plasmids are previously reported <sup>1</sup> and based on isolate hCoV-341 19/Botswana/R40B58 BHP 3321001245/2021 (GISAID Accession ID: EPI ISL 6640919) 342 343 and isolate hCoV-19/England/PHEC-4G0AFZF7/2021 (GISAID Accession ID: EPI ISL 8738174) respectively. The pCG1 SARS-2-Sdel18 XBB expression plasmid was 344 345 generated by Gibson assembly based on the expression vector for the spike of Omicron BA.2 346 and site directed mutagenesis was done to generate XBB.1.5. Expression plasmids pCAGGS-DsRed and pCG1-SARS-2-SDel18 BA.2.86 (based on the isolate hCoV-19/Denmark/DCGC-347 647694/2023, EPI ISL 18114953) were kindly provided by the Laboratory of Stefan 348 349 Pöhlmann (Table 3, Supplementary data 3). Site directed mutagenesis (Q5® High-Fidelity 2X Master Mix, New England BioLabs) was utilized for the generation of the SARS-CoV-2 spike 350

351 BA.2.86 expression plasmid library containing single point mutations back to BA.2 spike.

352 Transformation was carried out using NEB® 10-beta Competent E. coli from New England

BioLabs (catalogue: C3019H). Primers are listed in Table 2, Supplementary data 3.

354

### 355 **Production and titration of Pseudo-viruses**

Production of pseudo-viruses was performed according to published protocol <sup>44</sup>. In brief, 293T cells were seeded in 6 well plates at a confluency of 70%. The next day, cells were transfected with expression plasmids for pCG1-SARS-2-S $\Delta$ 18 WT,

359 pCG1-SARS-2-SA18 BA2.86, pCG1-SARS-2-SA18 BA2, pCG1-SARS-2-SA18 BA2.86 360 XBB or pCG1-SARS-2-SA18 BA2.86 single point mutants. At 24 hours post transfection, cells 361 were incubated for 1 hour with a replication deficient VSV (VSV\* $\Delta G$ ) expressing enhanced green fluorescent protein (eGFP) and firefly luciferase at an MOI of 3. VSV\* $\Delta G$  was kindly 362 provided by the lab of Gert Zimmer. Subsequently, cells were washed with phosphate buffered 363 364 saline (PBS) and incubated with anti-VSV-G antibody (mouse hybridoma supernatant from 365 CRL-2700; ATCC) in order to neutralize residual input virus. At 12 hours post infection, supernatants were harvested and cleared from cell debris by centrifugation and stored at -80C 366 367 for later use. For titration, aliquots of the pseudo-virus were serially diluted threefold in duplicates, starting with a 1:10 dilution in a 96-well plate, totaling eleven dilutions. The last 368 369 column served as a control with cells but no pseudo-virus. Confluent VeroE6 cells in the 96-370 well format were infected with the diluted virus, then incubated for 24 hours at 37°C with 5% 371 CO2. GFP+ infected cells were counted using the IncuCyte S3 (Sartorius), which performed whole-well scans (4x) in phase contrast and green fluorescence (300ms exposure). The 372 373 IncuCyte GUI software (versions 2019B Rev1 and 2021B) was used for counting of fluorescent 374 foci and counts were exported to Excel 2016. The average number of infected cells was 375 calculated for three different pseudo-virus dilutions, and this number was multiplied by the

dilution factor to determine the focus forming units (ffu) per ml. The pseudo-virus titer wascalculated as the mean ffu/ml from the three pseudo-virus dilutions.

378

#### 379 Neutralization assay

Neutralization assays were based on a previously published protocol  $^{1}$ . In brief, all plasma 380 381 samples utilized in this study were heat inactivated at 56 °C for 30 minutes, 10 fold diluted in DMEM [1% Penicillin-Streptomycin, 1% L-Glu, 5% FBS], and stored at 4 °C for further use. 382 383 Pseudo-viral particles (600pfu/well±30%) were incubated for one hour in a 96 well microtiter 384 plate with two-fold diluted serum samples in DMEM [1% Penicillin-Streptomycin, 1% L-Glu, 385 5% FBS] ranging from 1:100 to 1:51200. Pseudo-virus particles were incubated in the absence 386 of plasma as controls indicating 0% inhibition. After incubation, the serum/virus samples were 387 transferred onto a confluent VeroE6 96 well plate. After a 24-hour incubation, plates were fixed with 4% paraformaldehyde (PFA) and stored at 4 °C until readout. GFP+ infected cells were 388 389 counted using an IncuCyte S3 (Sartorius) performing whole-well scans (4x) in phase contrast 390 and green fluorescence settings (300ms exposure). Automated segmentation and counting of 391 fluorescent foci defined as green fluorescent protein GFP+-single cells was performed using 392 the IncuCyte GUI software (versions 2019B Rev1 and 2021B). Pseudo-virus neutralization 393 titer 50 (PVNT50) values were determined by a non-linear regression model. The lower limit 394 of confidence (LLOC) was set at a PVNT50 of 50. Non-responders were defined as individuals 395 with PVNT50<60 (dashed line). All PVNT50<10 are set at 10 for visualization purposes. Due 396 to technical limitations (the limited volume of plasma samples and the technical challenges associated with assaying 30 samples against ~40 different pseudoviruses in duplicates), every 397 398 pseudovirus was tested on at least 20 individual, randomly chosen plasma samples. These were 399 arranged so that over 80% of the plasma originated from the same set of patients. This approach

aimed to minimize variability due to differing inherent potencies among plasma samples. Alldata are presented as numerical titers for each study participant in the supplementary data 2.

402

## 403 **Ethics committee Approval**

The collection of all plasma samples was approved by the research ethics committee of the Institutional Review Board of Hannover Medical School (8973\_BO\_K\_2020). All donors provided written consent for plasma donation and use research purposes, consent for publishing identifiers such as sex and age was also acquired.

#### 408 Plasma Samples

409 The number of participants within this analysis is n=30. Median age is 45 years (interquartile 410 range (IQR) 33 to 56). Male to female ratio is 1:2. Among these participants, 30% were 411 vaccinated with three vaccine doses, 60% were vaccinated with four vaccine doses, and 10% were vaccinated with more than four doses. Ten participants (33.3%) were vaccinated with the 412 413 bivalent WT/BA.4/5 vaccine. The median time in months since last recorded SARS-CoV-2 414 infection for the patients with known infections is 15 (IQR 13 to 18). The median number of 415 months since the last known vaccination dates within our cohort is 13,5 months (IQR 11 to 22). 416 All participants are part of the COVID-19 contact study, to monitor anti-SARS-CoV-2 immune 417 responses in healthcare workers at Hannover Medical School (MHH). All participants donated 418 blood directly prior to vaccination with 30µg of the updated BNT162b2 Omicron XBB.1.5 419 vaccine (Raxtozinameran, BioNTech, Mainz, Germany) in September 2023 and were followed-up for another blood collection 15-16 days post vaccination <sup>35</sup>. Plasma was separated 420 421 from collected blood and stored at -80 °C for long term storage and 4°C for immediate use. 422 Detailed information is provided in Supplementary data 1.

423

424

#### 425 Viral genome copy number

426 To quantify the VSV genome copy numbers in samples, digital droplet PCR (ddPCR) was 427 performed on the VSV-N gene. Supernatants containing viral particles were treated with 428 nuclease muncher (Abcam) by incubating with 2 U/ml for >60 min at 37°C before RNA 429 isolation using the QIAamp Viral RNA Mini kit according to the manufacturer's instructions. 430 For ddPCR, a one-step RT-ddPCR kit (Bio-Rad) was used combined with primers and probe detecting the VSV N (qRT VSV-N\_F: ATGACAAATGGTTGCCTTTGTATCTACTT, 431 432 ACGACCTTCTGGCACAAGAGGT, qRT VSV-N R: **VSV-NcDNA** probe: 433 /56FAM/ACAGAGTGG/ZEN/GCAGAACACAAATGCCT/3IABkFQ/) and, to exclude the 434 presence of non-enveloped RNA in the sample, we used the human ACTB transcript 435 (ACTBcDNA\_F: GAGGAGCACCCCGTG, ACTBcDNA\_R: GCCTGGATAGCAACGTAC, 436 ACTBcDNA\_probe: [HEX]CCCAGATCATGTTTGAGACCTTCAACACC[BHQ1]) PCR 437 was done with a Bio-Rad C1000 Touch thermo cycler, encapsulation and read-out were done 438 with the Bio-Rad QX200 system. Data analysis was carried out with Bio-Rad QX Manager 439 Standard Edition (version 2.1.0.25).

440

#### 441 Statistical analysis

442 Statistical analysis was performed using GraphPad Prism 9.0 (GraphPad software). 443 Neutralization titers were plotted as geometric mean titers. A two sided paired non-parametric 444 Friedman test was performed for non-normally distributed data. P values less than 0.05 were 445 considered significant ns, p > 0.05; \*,  $p \le 0.05$ ; \*\*,  $p \le 0.01$ ; \*\*\*,  $p \le 0.001$ ).

#### 446 **Data availability**

447 Values for neutralization titers and information on plasma donors are provided in
448 Supplementary data 1 and 2. Data underlying the generation of the figures are provided as a
449 source data file: Source Data.

#### 450 References

| 451 | 1  | Katzmarzyk, M. et al. Systematical assessment of the impact of single spike                  |
|-----|----|--|
| 452 |    | mutations of SARS-CoV-2 Omicron sub-variants on the neutralization capacity of               |
| 453 |    | post-vaccination sera. Front Immunol 14, 1288794, doi:10.3389/fimmu.2023.1288794             |
| 454 |    | (2023).  |
| 455 | 2  | Callaway, E. Why a highly mutated coronavirus variant has scientists on alert. <i>Nature</i> |
| 456 |    | <b>620</b> , 934, doi:10.1038/d41586-023-02656-9 (2023).                                     |
| 457 | 3  | Focosi, D., Spezia, P. G. & Maggi, F. SARS-CoV-2 BA.2.86 ("Pirola"): Is it Pi or             |
| 458 |    | Just Another Omicron Sublineage? Vaccines (Basel) 11,  |
| 459 |    | doi:10.3390/vaccines11111634 (2023).   |
| 460 | 4  | Harris, E. CDC Assesses Risk From BA.2.86, Highly Mutated COVID-19 Variant.                  |
| 461 |    | Jama 330, 1029, doi:10.1001/jama.2023.16105 (2023).  |
| 462 | 5  | Rasmussen, M. et al. First cases of SARS-CoV-2 BA.2.86 in Denmark, 2023. Euro                |
| 463 |    | Surveill 28, doi:10.2807/1560-7917.Es.2023.28.36.2300460 (2023).                             |
| 464 | 6  | Wannigama, D. L. et al. Tracing the new SARS-CoV-2 variant BA.2.86 in the                    |
| 465 |    | community through wastewater surveillance in Bangkok, Thailand. Lancet Infect Dis            |
| 466 |    | <b>23</b> , e464-e466, doi:10.1016/s1473-3099(23)00620-5 (2023).                             |
| 467 | 7  | Lambrou, A. S. et al. Early Detection and Surveillance of the SARS-CoV-2 Variant             |
| 468 |    | BA.2.86 - Worldwide, July-October 2023. MMWR Morb Mortal Wkly Rep 72, 1162-                  |
| 469 |    | 1167, doi:10.15585/mmwr.mm7243a2 (2023).   |
| 470 | 8  | Reeve, L. et al. High attack rate in a large care home outbreak of SARS-CoV-2                |
| 471 |    | BA.2.86, East of England, August 2023. Euro Surveill 28, doi:10.2807/1560-                   |
| 472 |    | 7917.Es.2023.28.39.2300489 (2023).   |
| 473 | 9  | Hoffmann, M. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and                    |
| 474 |    | Is Blocked by a Clinically Proven Protease Inhibitor. Cell 181, 271-280.e278,                |
| 475 |    | doi:10.1016/j.cell.2020.02.052 (2020).   |
| 476 | 10 | Lusvarghi, S. et al. Key Substitutions in the Spike Protein of SARS-CoV-2 Variants           |
| 477 |    | Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can                 |
| 478 |    | Modify the Effects. J Virol 96, e0111021, doi:10.1128/jvi.01110-21 (2022).                   |
| 479 | 11 | Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable           |
| 480 |    | bat origin. Nature 579, 270-273, doi:10.1038/s41586-020-2012-7 (2020).                       |
| 481 | 12 | Yang, S. et al. Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86.         |
| 482 |    | Lancet Infect Dis 23, e457-e459, doi:10.1016/s1473-3099(23)00573-x (2023).                   |
| 483 | 13 | Uriu, K. <i>et al.</i> Transmissibility, infectivity, and immune evasion of the SARS-CoV-2   |
| 484 |    | BA.2.86 variant. Lancet Infect Dis 23, e460-e461, doi:10.1016/s1473-3099(23)00575-           |
| 485 |    | 3 (2023).  |
| 486 | 14 | Wang, Q. et al. Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike.              |
| 487 |    | Nature, doi:10.1038/s41586-023-06750-w (2023).   |
| 488 | 15 | Qian, W. et al. XBB.1.5 monovalent mRNA vaccine booster elicits robust                       |
| 489 |    | neutralizing antibodies against emerging SARS-CoV-2 variants. bioRxiv,                       |
| 490 |    | 2023.2011.2026.568730, doi:10.1101/2023.11.26.568730 (2023).                                 |
| 491 | 16 | Dadonaite, B. et al. Full-spike deep mutational scanning helps predict the                   |
| 492 |    | evolutionary success of SARS-CoV-2 clades. bioRxiv,  |
| 493 |    | doi:10.1101/2023.11.13.566961 (2023).  |
| 494 | 17 | Pastorio, C. et al. Determinants of Spike infectivity, processing, and neutralization in     |
| 495 |    | SARS-CoV-2 Omicron subvariants BA.1 and BA.2. Cell Host Microbe 30, 1255-                    |
| 496 |    | 1268.e1255, doi:10.1016/j.chom.2022.07.006 (2022).   |

| 497        | 18 | Abassi, L. et al. Evaluation of the Neutralizing Antibody STE90-C11 against SARS-   |
|------------|----|---|
| 498        |    | CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns. Viruses 15,  |
| 499        |    | doi:10.3390/v15112153 (2023).   |
| 500        | 19 | Miller, J. et al. Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants  |
| 501        |    | BQ.1.1 and XBB.1. N Engl J Med 388, 662-664, doi:10.1056/NEJMc2214314 (2023).   |
| 502        | 20 | Yue, C. et al. ACE2 binding and antibody evasion in enhanced transmissibility of  |
| 503        |    | XBB.1.5. Lancet Infect Dis 23, 278-280, doi:10.1016/s1473-3099(23)00010-5 (2023).   |
| 504        | 21 | Wang, Q. et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1,   |
| 505        |    | BA.4 and BA.5. <i>Nature</i> <b>608</b> , 603-608, doi:10.1038/s41586-022-05053-w (2022).                                     |
| 506        | 22 | McCallum, M. et al. N-terminal domain antigenic mapping reveals a site of   |
| 507        |    | vulnerability for SARS-CoV-2. Cell 184, 2332-2347.e2316,  |
| 508        |    | doi:10.1016/j.cell.2021.03.028 (2021).  |
| 509        | 23 | Vellas, C. et al. Resistance mutations in SARS-CoV-2 omicron variant in patients  |
| 510        |    | treated with sotrovimab. Clin Microbiol Infect 28, 1297-1299,   |
| 511        |    | doi:10.1016/j.cmi.2022.05.002 (2022).   |
| 512        | 24 | Mykytyn, A. Z., Fouchier, R. A. & Haagmans, B. L. Antigenic evolution of SARS   |
| 513        |    | coronavirus 2. <i>Curr Opin Virol</i> <b>62</b> , 101349, doi:10.1016/j.coviro.2023.101349 (2023).                            |
| 514        | 25 | Huo, J. <i>et al.</i> A delicate balance between antibody evasion and ACE2 affinity for                                       |
| 515        |    | Omicron BA.2.75. <i>Cell Rep</i> <b>42</b> , 111903, doi:10.1016/j.celrep.2022.111903 (2023).                                 |
| 516        | 26 | Qu, P. <i>et al.</i> Evasion of neutralizing antibody responses by the SARS-CoV-2 BA.2.75                                     |
| 517        |    | variant. <i>Cell Host Microbe</i> <b>30</b> , 1518-1526.e1514, doi:10.1016/j.chom.2022.09.015                                 |
| 518        | 27 | (2022).   |
| 519        | 27 | Tunyasuvunakool, K. <i>et al.</i> Highly accurate protein structure prediction for the human                                  |
| 520        | 20 | proteome. <i>Nature</i> <b>596</b> , 590-596, doi:10.1038/s41586-021-03828-1 (2021).  |
| 521        | 28 | Richard, E. <i>et al.</i> Protein complex prediction with AlphaFold-Multimer. <i>bioRxiv</i> ,                                |
| 522        | 20 | 2021.2010.2004.463034, doi:10.1101/2021.10.04.463034 (2022).  |
| 523        | 29 | Zhang, L. <i>et al.</i> SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing  |
| 524<br>525 |    | antibodies with high efficiency. <i>Cell</i> <b>187</b> , 596-608.e517,   |
| 525<br>526 | 20 | doi:10.1016/j.cell.2023.12.025 (2024).  |
| 526        | 30 | Yuan, Y. <i>et al.</i> Cryo-EM structures of MERS-CoV and SARS-CoV spike  |
| 527<br>528 |    | glycoproteins reveal the dynamic receptor binding domains. <i>Nat Commun</i> <b>8</b> , 15092, doi:10.1028/nacmms15002 (2017) |
| 528        | 31 | doi:10.1038/ncomms15092 (2017).<br>Colson, P. <i>et al.</i> Emergence of a second SARS-CoV-2 variant with a tremendous        |
| 529<br>530 | 51 | genetic leap from its ancestors. J Med Virol <b>95</b> , e29124, doi:10.1002/jmv.29124  |
| 530<br>531 |    | (2023).   |
| 532        | 32 | Sheward, D. J. <i>et al.</i> Sensitivity of the SARS-CoV-2 BA.2.86 variant to prevailing                                      |
| 533        | 52 | neutralising antibody responses. <i>Lancet Infect Dis</i> 23, e462-e463, doi:10.1016/s1473-                                   |
| 535<br>534 |    | 3099(23)00588-1 (2023).   |
| 535        | 33 | Berkhout, B. & Herrera-Carrillo, E. SARS-CoV-2 Evolution: On the Sudden   |
| 536        | 55 | Appearance of the Omicron Variant. J Virol <b>96</b> , e0009022, doi:10.1128/jvi.00090-22                                     |
| 537        |    | (2022).   |
| 538        | 34 | Raglow, Z. <i>et al.</i> SARS-CoV-2 shedding and evolution in immunocompromised hosts   |
| 539        | 54 | during the Omicron period: a multicenter prospective analysis. <i>medRxiv</i> ,   |
| 540        |    | doi:10.1101/2023.08.22.23294416 (2023).   |
| 541        | 35 | Stankov, M. V. <i>et al.</i> Humoral and cellular immune responses following BNT162b2   |
| 542        | 55 | XBB.1.5 vaccination. <i>Lancet Infect Dis</i> , doi:10.1016/s1473-3099(23)00690-4 (2023).                                     |
| 543        | 36 | Chi, X. <i>et al.</i> A neutralizing human antibody binds to the N-terminal domain of the                                     |
| 544        | 20 | Spike protein of SARS-CoV-2. <i>Science</i> <b>369</b> , 650-655,   |
| 545        |    | doi:doi:10.1126/science.abc6952 (2020).   |
|            |    |   |

| 546 | 37 | Suryadevara, N. et al. An antibody targeting the N-terminal domain of SARS-CoV-2                    |
|-----|----|---|
| 547 |    | disrupts the spike trimer. J Clin Invest 132, doi:10.1172/jci159062 (2022).                         |
| 548 | 38 | Wang, Q. et al. Evolving antibody evasion and receptor affinity of the Omicron                      |
| 549 |    | BA.2.75 sublineage of SARS-CoV-2. iScience 26, 108254,  |
| 550 |    | doi:10.1016/j.isci.2023.108254 (2023).  |
| 551 | 39 | Wang, Q. et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and                    |
| 552 |    | XBB subvariants. Cell 186, 279-286.e278, doi:10.1016/j.cell.2022.12.018 (2023).                     |
| 553 | 40 | Wang, Q. et al. Antigenic characterization of the SARS-CoV-2 Omicron subvariant                     |
| 554 |    | BA.2.75. Cell Host Microbe 30, 1512-1517.e1514, doi:10.1016/j.chom.2022.09.002                      |
| 555 |    | (2022).   |
| 556 | 41 | Lester, S. et al. Middle East respiratory coronavirus (MERS-CoV) spike (S) protein                  |
| 557 |    | vesicular stomatitis virus pseudoparticle neutralization assays offer a reliable                    |
| 558 |    | alternative to the conventional neutralization assay in human seroepidemiological                   |
| 559 |    | studies. Access Microbiol 1, e000057, doi:10.1099/acmi.0.000057 (2019).                             |
| 560 | 42 | Tolah, A. M. K. et al. Evaluation of a Pseudovirus Neutralization Assay for SARS-                   |
| 561 |    | CoV-2 and Correlation with Live Virus-Based Micro Neutralization Assay.                             |
| 562 |    | Diagnostics (Basel) 11, doi:10.3390/diagnostics11060994 (2021).                                     |
| 563 | 43 | Quandt, J. et al. Omicron BA.1 breakthrough infection drives cross-variant                          |
| 564 |    | neutralization and memory B cell formation against conserved epitopes. Sci Immunol                  |
| 565 |    | 7, eabq2427, doi:10.1126/sciimmunol.abq2427 (2022).   |
| 566 | 44 | Berger Rentsch, M. & Zimmer, G. A vesicular stomatitis virus replicon-based                         |
| 567 |    | bioassay for the rapid and sensitive determination of multi-species type I interferon.              |
| 568 |    | <i>PLoS One</i> <b>6</b> , e25858, doi:10.1371/journal.pone.0025858 (2011).                         |
| 569 | 45 | Jumper, J. <i>et al.</i> Highly accurate protein structure prediction with AlphaFold. <i>Nature</i> |
| 570 |    | <b>596</b> , 583-589, doi:10.1038/s41586-021-03819-2 (2021).  |
| 571 |    |   |
| 572 |    |   |
| 512 |    |   |
| 573 |    |   |
| 515 |    |   |
| 574 |    |   |
| 571 |    |   |
| 575 |    |   |
| 010 |    |   |
| 576 |    |   |
|     |    |   |
| 577 |    |   |
|     |    |   |
| 578 |    |   |
|     |    |   |
| 579 |    |   |
|     |    |   |
| 580 |    |   |
|     |    |   |
| 581 |    |   |
|     |    |   |
| 582 |    |   |
|     |    |   |
| 583 |    |   |
|     |    |   |

#### 584 ACKNOWLEDGEMENTS:

- 585 This research was funded by the Helmholtz Association through Helmholtz Campaign
- 586 COVIPA (KA1-Co-02) to L.C-S. and EU-Partnering grant MCMVaccine (PIE-008) to L.C-S.
- and S.P. Funding to L.C-S and S.P. was also provided by the Ministry of Science and Culture
- 588 of Lower Saxony, through the COFONI Network, flex fund projects 6FF22 and 10FF22. L.C-
- 589 S also obtained funding from the German Scientific Foundation (DFG) through grants EXC
- 590 2155 "RESIST"—Project ID 39087428 and FOR2830, project 5.
- 591 G.M.N.B. and A.D.-J. acknowledge funding from Ministry of Science and Culture of Lower
- 592 Saxony (14-76103-184, COFONI Network, project 4LZF23), G.M.N.B. acknowledges
- 593 funding by the European Regional Development Fund (ZW7-85151373), and A.D.-J.
- acknowledge funding by European Social Fund (ZAM5-87006761).
- We thank Ayse Barut, Yuliia Polianska, Inge Hollatz-Rangosch and Karina Watzke for expert technical assistance, Natascha Gödecke for support with biosafety compliance and Gert Zimmer (Institute of Virology and Immunology, Mittelhäusern, Switzerland) for providing the VSV pseudo-virus system. We also thank the CoCo Study participants for their support and the entire CoCo study team, especially Annika Heidemann and Luis Manthey, for technical and logistical support.

#### 601 AUTHOR CONTRIBUTIONS

- 602 Conceptualization: LC-S; Methodology: LC-S; NB; Investigation: NB, TL, HM, KM, HJ, SS.
- 603 UK, UR; Formal analysis: NB, SS, WB, UR, AD-J, GMN, LC-S; Resources: SP, MH,
- 604 AC,MVS, AD-J, and GMN; Funding acquisition: LC-S; Writing original draft: NB.; Writing
- 605 review & editing: all authors.

### 606 **COMPETING INTERESTS**

607 L.C-S. served as an advisor to Sanofi unrelated to this work. G.M.N.B. served as advisor for

608 Moderna unrelated to this work, A.D-J served as an advisor for Pfizer unrelated to this work,

609 S.P. and M.H. conducted contract research (testing of vaccinee plasma for neutralizing activity

610 against SARS-CoV-2) for Valneva unrelated to this work. S.P. served as advisor for BioNTech,

611 unrelated to this work. H.J. served as advisor on COVID neutralization assays for WHO and

- 612 CEPI, unrelated to this work. The other authors declare no competing interests.
- 613

614

#### 615 FIGURES LEGENDS

616

#### 617 Figure 1. Overview of BA.2.86 lineage specific spike protein mutations relative to BA.2

(A) Schematic representation of the SARS-CoV-2 spike domains and amino acid changes 618 619 indicated for BA.2.86, and shared by XBB.1.5, and EG.5.1 compared to the spike of BA.2. Further mutations within XBB.1.5 and EG.5.1 relative to BA.2 are not shown, as only sites 620 621 mutated within BA.2.86 are represented. N-terminal domain (NTD, blue), receptor binding 622 domain (RBD, green), Subdomains 1 and 2 (SD1 and SD2, orange), S2 subunit (orange). Created in BioRender. Bdeir, N. (2024) BioRender.com/m05k539 and in the references add: 623 Bdeir, N. (2024). Figure 1A. Created in BioRender. BioRender.com/m05k539. (B) Model of 624 the trimeric spike protein of BA.2.86, calculated with AlphaFold2/AlphaFold-Multimer<sup>28,45</sup>. 625 The N-terminal secretion signal (15 residues) and the C-terminal membrane-anchoring 626 627 sequence (112 residues) were omitted from calculations, leading to 3372 residues in the final model. Domains have been colored according to panel (A), and one of five independently 628 629 calculated models is shown. Spheres represent the location of mutations with respect to the 630 spike protein of BA.2. The positions of deletions are colored in green, red spheres indicate mutations that lead to enhanced immune escape of BA.2.86, other mutations are shown in blue. 631 632 For clarity, mutations are only shown in one chain of the spike trimer. (C) Magnified view of 633 one trimer extracted from the model shown in (B) and shown in the same orientation.

634

635

| 636 | Figure 2. BA.2.86 and JN.1 efficiently evade neutralization in double boostered                                   |
|-----|---|
| 637 | individuals, but the adapted XBB.1.5 vaccine booster enhances protection against both.                            |
| 638 | (A) Particles pseudo-typed with the indicated S proteins were pre-incubated for one hour at                       |
| 639 | 37 °C with plasma dilutions from double boostered health care workers (biological replicates                      |
| 640 | n=30) (2A) or with plasma dilutions following vaccination with an adapted XBB.1.5 booster                         |
| 641 | (biological replicates n=30) (2B). Pseudo-virus neutralization titer 50 (PVNT50) was                              |
| 642 | calculated using the least squares fit using a variable slope, using a four-parameter nonlinear                   |
| 643 | regression model and values were plotted as geometric mean. Geometric mean standard                               |
| 644 | deviation bars are shown in black. The lower limit of confidence (LLOC) was set at a PVNT50                       |
| 645 | of 50. Non responders are defined as individuals below 60 (dashed line). All PVNT50 below                         |
| 646 | 10 are set at 10 for visualization purposes. The assay was performed in technical duplicates                      |
| 647 | and with negative controls to assess the virus input of each used pseudo-virus in the absence                     |
| 648 | of plasma antibodies. Percentage of positive responders, geometric means, and fold change                         |
| 649 | neutralization over WT-Wuhan <sub>pp</sub> are shown on top. Friedman two sided non parametric paired             |
| 650 | test (ns, p > 0.05; *, p $\leq$ 0.05; **, p $\leq$ 0.01; ***, p $\leq$ 0.001). Percentage of positive responders, |
| 651 | geometric means, and fold change neutralization over WT-Wuhan <sub>pp</sub> are shown on top. Source              |
| 652 | data are provided as a Source Data file.  |

653

#### Figure 3. Mapping mutations in the NTD for effects of BA.2.86 neutralization efficiency 654 655 in double boostered individuals

(A) Neutralization assessment for particles pseudo-typed with mutations within the NTD of 656 BA.2.86. Each mutant shown contains a single mutation reverting the amino acid mutation in 657 658 BA.2.86 to the corresponding amino acid within BA.2. Particles pseudo-typed with the indicated S proteins were preincubated for one hour at 37 °C with plasma dilutions from double 659

660 boostered health care workers with non-adapted immunogens . The numbers of biological 661 replicates corresponding to individual plasma samples are shown on top. Pseudo-virus neutralization titer 50 (PVNT50) was calculated using the least squares fit using a variable 662 663 slope, using a four-parameter nonlinear regression model. The lower limit of confidence 664 (LLOC) was set at a PVNT50 of 50. Non responders are defined as individuals below 60 (dashed line) All PVNT50 below 10 are set at 10 for visualization purposes. The assay was 665 666 performed in technical duplicates and with negative controls to assess the virus input of each 667 used pseudo-virus in the absence of plasma antibodies. Percentage of positive responders, 668 geometric means, and fold change neutralization over WT-Wuhan<sub>pp</sub> are shown on top. 669 Geometric mean standard deviation bars are shown in black. (B) Individual neutralization data 670 for particles pseudo-typed with mutations within the NTD of BA.2.86. Statistical significance was assessed by Friedman two sided non parametric paired test (ns, p > 0.05; \*,  $p \le 0.05$ ; \*\*, 671  $p \le 0.01$ ; \*\*\*,  $p \le 0.001$ ). Source data are provided as a Source Data file. 672

673

## Figure 4. Mapping mutations in the RBD for effects of BA.2.86 neutralization efficiency in double boostered individuals

676

(A) Neutralization assessment for particles pseudo-typed with mutations within the RBD of 677 678 BA.2.86. Each mutant shown contains a single mutation reverting the amino acid mutation in 679 BA.2.86 to the corresponding amino acid within BA.2. Particles pseudo-typed with the 680 indicated S proteins were pre-incubated with serum dilutions from immunized health care workers for one hour at 37 °C. The numbers of biological replicates corresponding to individual 681 682 plasma samples are shown on top. The lower limit of confidence (LLOC) was set at a PVNT50 of 50. Non responders are defined as individuals below 60 (dashed line). Non responders are 683 684 defined as individuals below this threshold. All PVNT50 below 10 are set at 10 for

visualization purposes. The assay was with negative controls to assess the virus input of each used pseudo-virus in the absence of plasma antibodies. Percentage of positive responders, geometric means, and fold change neutralization over BA.2<sub>pp</sub> are shown on top. Geometric mean standard deviation bars are shown in black. (B) Individual neutralization data for particles pseudo-typed with mutations within the RBD of BA.2.86. Statistical significance was assessed by Friedman two sided non parametric paired test (ns, p > 0.05; \*, p ≤ 0.05; \*\*, p ≤ 0.01; \*\*\*, p ≤ 0.001). Source data are provided as a Source Data file.

692

# Figure 5. Mapping mutations in the S1/S2 domain for effects of BA.2.86 neutralization efficiency in double boostered individuals

695

696 (A) Neutralization assessment for particles pseudo-typed with mutations within the S1/S2 and 697 S2 domain of BA.2.86. Each mutant shown contains a single mutation reverting the amino acid 698 mutation in BA.2.86 to the corresponding amino acid within BA.2. Particles pseudo-typed with 699 the indicated S proteins were preincubated for one hour at 37 °C with plasma dilutions from 700 double boostered health care workers with non-adapted immunogens. The numbers of 701 biological replicates corresponding to individual plasma samples are shown on top. Pseudo-702 virus neutralization titer 50 (PVNT50) was calculated using the least squares fit using a variable 703 slope, using a four-parameter nonlinear regression model. The lower limit of confidence 704 (LLOC) was set at a PVNT50 of 50. Non responders are defined as individuals below 60 705 (dashed line). All PVNT50 below 10 are set at 10 for visualization purposes. The assay was 706 performed with negative controls to assess the virus input of each used pseudo-virus in the 707 absence of plasma antibodies. Percentage of positive responders, geometric means, and fold 708 change neutralization over BA.2<sub>pp</sub> are shown on top. Geometric mean standard deviation bars 709 are shown in black. (B) Individual neutralization data for particles pseudo-typed with mutations

within the S1/S2 and S2 domain of BA.2.86. Statistical significance was assessed by Friedman two sided nonparametric paired test (ns, p > 0.05; \*,  $p \le 0.05$ ; \*\*,  $p \le 0.01$ ; \*\*\*,  $p \le 0.001$ ). Source data are provided as a Source Data file.


713

# Figure 6: Reversions insMPLF16Δ, K460N, K554E and to lesser extent insY144, K484A, and S621P enhance the neutralization efficiency of plasma samples post BNT162b2 XBB.1.5 vaccination.


717 (A-F) Neutralization assessment for pseudo-typed particles with plasma post BNT162b2 718 XBB.1.5 vaccination. Each mutant shown contains a single mutation reverting the amino acid 719 mutation in BA.2.86 to the corresponding amino acid within BA.2. Particles pseudo-typed with 720 the indicated S proteins were pre-incubated for one hour at 37 °C with plasma dilutions from 721 double boostered health care workers. Pseudo-virus neutralization titer 50 (PVNT50) was 722 calculated using the least squares fit using a variable slope, using a four-parameter nonlinear regression model. The lower limit of confidence (LLOC) was set at a PVNT50 of 50. Non 723 responders are defined as individuals below this 60 (dashed line). All PVNT50 below 10 are 724 725 set at 10 for visualization purposes. The assay was performed in technical duplicates and with 726 negative controls to assess the virus input of each used pseudo-virus in the absence of plasma 727 antibodies. Statistical significance was assessed by Friedman two sided nonparametric paired test (ns, p > 0.05; \*,  $p \le 0.05$ ; \*\*,  $p \le 0.01$ ; \*\*\*,  $p \le 0.001$ ). Source data are provided as a 728 729 Source Data file.

- 730
- 731


SARS-CoV2 spike




C) B) RBD V445H G4465 NTD N450D / L452W / R493Q ins16MPLF F1575 / V127F NTD R403K D339H F486P A484K ΔV483 N481K 1332V ∆Y144 H245N SD2 ΔV70 · ΔH69 N460K R21T A264D ... ΔN211 K356T RBD L2121 L216F **S**2 SD1 S50L




#### A) Before XBB.1.5 booster vaccination



#### B) After XBB.1.5 booster vaccination





10<sup>2</sup>

10<sup>1</sup>

10

842.38 D284A 84.286

10 (Re

101

10

BA286N2ASH

BA.2.86

PVNT50

10

101

100


84.286F216L


8A.2.86


#### Neutralisation titers for NTD specific BA.2.86pp mutants pre XBB.1.5 adapted vaccine


Neutralisation titers for RBD specific BA.2.86pp mutants pre XBB.1.5 adapted vaccine


A) Geometric mean titer: 100 276 84 106 242 230 196 Fold reduction (vs. BA.2): -Sample number: 
























BA.2.86 D450N





BA.2.86















BA.2.86 Q493R

Neutralisation titers for S1/S2 and S2 specific BA.2.86pp mutants pre XBB.1.5 adapted vaccine



Neutralisation titers for BA.2.86pp mutants post XBB.1.5 adapted vaccine

